Our mission is to identify
and develop potent and safe
human monoclonal antibodies
to address unmet medical needs
in patients suffering from
severe viral infections
Medical Need
Our lead asset, SPK004, addresses a severe unmet medical need in kidney transplant recipients.
Due to the immunosuppressive treatments required to prevent graft rejection, these patients are highly susceptible to the reactivation of a dormant virus known as BK virus (BKV).
BKV reactivation can severely compromise graft function by leading to BK virus–associated nephropathy, which may ultimately result in graft loss. Currently, there are no approved antiviral therapies specifically targeting BKV infection, leaving clinicians with limited and suboptimal management options.
Our Values
At SpikImm, our work is guided by three core values.
Patients: we are committed to supporting immunocompromised patients facing serious viral infections by delivering innovative, effective preventive solutions that improve outcomes.
Mindset: as a small enterprise, we rely on the quality and expertise of our people and the agility of our organization to move fast and deliver with precision.
Ethics & Quality: we hold ourselves to uncompromising ethical and quality standards, because innovation and medical intervention demand rigor, integrity, and trust.